Fact CheckerSign in

NCT06323044Recruiting

MedSupport Intervention to Identify and Address Barriers to Pediatric Medication Adherence

MedSupport: A Novel Multilevel Intervention to Identify and Address Barriers to Pediatric Medication Adherence

Source: ClinicalTrials.gov · Last updated 12 Aug 2026

Brief summary (registry, in English)

This clinical trial identifies and addresses barriers to pediatric medication adherence among families of children with acute lymphoblastic leukemia. Pediatric nonadherence (noncompliance) to medication is a significant public health problem, and rigorous research repeatedly documents that nonadherence increases risk for hospitalization, healthcare cost, disease progression, and death. Pediatric acute lymphoblastic leukemia (ALL) patients who miss 5% of 6-mercaptopurine (6-MP) doses within the 2-year 6-MP regimen have a 2.7-fold risk of cancer that comes back after a period of improvement (relapse). To address these families' needs, researchers have developed MedSupport, a theory-based multilevel intervention with targets at the organizational, healthcare team, and caregiver levels that is designed to address root barriers to medication adherence. This study is being done to better understand families' experiences giving their child oral chemotherapy at home and to help families cope with the day-to-day challenges of giving their child medication.

Status (registry)
Recruiting
Study type
Interventional
Enrollment
150 (estimated)
First submitted
14 Mar 2024
Start date
11 Feb 2025
Primary completion date
31 Mar 2029
Lead sponsor
Roswell Park Cancer Institute
NCT number
NCT06323044

What you commit to

  • Study type: Interventional
  • Planned participants: 150
  • From 11 Feb 2025 to the primary completion date, 31 Mar 2029
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other

  • Parent is unwilling or unable to follow protocol requirements.

Who the study is looking for

  • Parent of a child diagnosed with acute lymphoblastic leukemia (ALL)
  • Child patient age 365 days to \< 19 years at time of study entry.
  • Parent's child patient's therapy must include 6-mercaptopurine (6-MP) administered orally or by nasogastric (NG) tube.
  • Verbal fluency in English, or Spanish
  • Parent has a smartphone or computer access with an Internet connection.
  • Participant must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure.

Sex: All · Accepts healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Roswell Park Cancer Institute
Coordinator of this site? Confirm its status
BuffaloUnited StatesRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.